Drugs / FOXP3-T4
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07697118 | Sep 2026 → Sep 2028 expected | immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FOXP3-T4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07697118 ↗ |
| Action | Restore | “conversion of the IPEX patient's CD4+T-cells into functional Treg-like cells by transducing them with an optimized bidirectional lentivirus vector expressing human FOXP3” NCT07697118 ↗ |
| Modality | Cell therapy | “FOXP3-T4 is a genetically modified cell therapy product consisting of autologous CD4+ T-cells transduced ex vivo” NCT07697118 ↗ |
| Route | Intravenous | “Each patient will receive a single IV infusion of FOXP3-T4” NCT07697118 ↗ |